These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 20632084)

  • 21. Fulvestrant ('Faslodex') in pre-treated patients with advanced breast cancer: a single-centre experience.
    Steger GG; Bartsch R; Wenzel C; Pluschnig U; Hussian D; Sevelda U; Locker GJ; Gnant MF; Jakesz R; Zielinski CC
    Eur J Cancer; 2005 Nov; 41(17):2655-61. PubMed ID: 16230005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine response after prior treatment with fulvestrant in postmenopausal women with advanced breast cancer: experience from a single centre.
    Cheung KL; Owers R; Robertson JF
    Endocr Relat Cancer; 2006 Mar; 13(1):251-5. PubMed ID: 16601292
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
    Kuter I; Gee JM; Hegg R; Singer CF; Badwe RA; Lowe ES; Emeribe UA; Anderson E; Sapunar F; Finlay P; Nicholson RI; Bines J; Harbeck N
    Breast Cancer Res Treat; 2012 May; 133(1):237-46. PubMed ID: 22286314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical development of fulvestrant ("Faslodex").
    Howell A; Abram P
    Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of fulvestrant 250 mg versus 500 mg in postmenopausal women with estrogen receptor-positive metastatic breast cancer and disease progression after antiestrogen therapy.
    Newman MJ; Jones LT; Kraft JM; Lee AR; Lech GM; Farrell NM; Phantumvanit V; Edwards RA
    J Oncol Pharm Pract; 2012 Dec; 18(4):394-401. PubMed ID: 22357638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fulvestrant for the treatment of advanced breast cancer in postmenopausal women: a Japanese study.
    Watanabe T; Sano M; Ohno S; Inaji H; Nishimura R; Shin E; Nomura Y; Morris C
    Anticancer Res; 2004; 24(2C):1275-80. PubMed ID: 15154660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women.
    Croxtall JD; McKeage K
    Drugs; 2011 Feb; 71(3):363-80. PubMed ID: 21319872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fulvestrant ("Faslodex"): clinical experience from the Compassionate Use Programme.
    Steger GG; Gips M; Simon SD; Lluch A; Vinholes J; Kaufman B; Wardley A; Mauriac L
    Cancer Treat Rev; 2005; 31 Suppl 2():S10-6. PubMed ID: 16198057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant ('Faslodex') in postmenopausal women with advanced breast cancer.
    Robertson JF; Harrison MP
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):346-8. PubMed ID: 12879276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.
    Robertson JF; Llombart-Cussac A; Rolski J; Feltl D; Dewar J; Macpherson E; Lindemann J; Ellis MJ
    J Clin Oncol; 2009 Sep; 27(27):4530-5. PubMed ID: 19704066
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer.
    Chadha MK; Ashraf U; Lawrence D; Tian L; Levine E; Silliman C; Escott P; Payne V; Trump DL
    Prostate; 2008 Sep; 68(13):1461-6. PubMed ID: 18618738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fulvestrant in postmenopausal women with advanced breast cancer.
    Bross PF; Baird A; Chen G; Jee JM; Lostritto RT; Morse DE; Rosario LA; Williams GM; Yang P; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2003 Oct; 9(12):4309-17. PubMed ID: 14555500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
    Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
    Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
    Franco S; Perez A; Tan-Chiu E; Frankel C; Vogel CL
    Breast Cancer Res Treat; 2004 Nov; 88(2):103-8. PubMed ID: 15564793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of fulvestrant in the management of postmenopausal breast cancer.
    Krell J; Januszewski A; Yan K; Palmieri C
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95--a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial.
    Thürlimann B; Hess D; Köberle D; Senn I; Ballabeni P; Pagani O; Perey L; Aebi S; Rochlitz C; Goldhirsch A
    Breast Cancer Res Treat; 2004 Jun; 85(3):247-54. PubMed ID: 15111763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.
    Emons G; Günthert A; Thiel FC; Camara O; Strauss HG; Breitbach GP; Kölbl H; Reimer T; Finas D; Rensing K;
    Gynecol Oncol; 2013 Jun; 129(3):495-9. PubMed ID: 23500091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fulvestrant in heavily pretreated postmenopausal women with advanced breast cancer].
    Martínez Marín V; Muñoz Martín AJ; Viñuela Benéitez MC; García Alfonso P; Alonso Muñoz A; Pérez Manga G
    Med Clin (Barc); 2009 Sep; 133(10):371-4. PubMed ID: 19339025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.